From California, USA:
I have a eight year old son diagnosed with reactive hypoglycemia. This was diagnosed after extensive gastric surgery when he was four. He recently started having high blood sugar readings. But he has not yet developed diabetes. His sugar always returns to normal ranges or goes below normal. There is no set amount of time it takes him to return to normal but he does. Could he be a candidate for the study trials I have read about on this web page? His islet cell test was normal as was his C-peptide. He is currently on multiple medications for other problems. Also is there any time frame as to when he will stop producing insulin on his own? His doctor said it is going to happen but not when. I feel like we are walking on eggshells.
From what you have told us I am not at all clear on what basis your doctor thinks that your son will inevitably get diabetes. One way to be sure whether or not he is at high risk to get Type 1 or autoimmune diabetes would be to get an antibody test done. If he has two or more of the three antibodies normally tested for and was still not clinically diabetic he would certainly be a candidate to get small doses of insulin by injection or oral insulin as part of the national DPT-1 trial.
There are of course other forms of diabetes that can develop in children of this age; but by and large they are quite rare.
Original posting 12 May 1998
Posted to Diagnosis and Symptoms
|Return to the Top of This Page|
Last Updated: Tuesday April 06, 2010 15:08:58
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.